婴儿在生命的第一年接受早期抗逆转录病毒治疗，其 CD4 计数会很高。
Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.
机构信息
Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Division of Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2023 Feb 8;76(3):e744-e747. doi: 10.1093/cid/ciac695.
Abstract
UNLABELLED
We followed 54 infants with in utero HIV after initiating very early antiretroviral treatment. At weeks 24 and 48, ≥80% had CD4 ≥1500 cells/mm3 and CD4% ≥25%. Routine Pneumocystis jirovecii pneumonia prophylaxis in the first year of life may not be necessary for all very early treated infants.
CLINICAL TRIALS REGISTRATION
NCT02140255.
摘要
未加标签
我们对 54 名在子宫内感染 HIV 的婴儿进行了研究，这些婴儿在非常早期就开始接受抗逆转录病毒治疗。在第 24 和 48 周时，≥80%的婴儿的 CD4 细胞≥1500 个/立方毫米，CD4%≥25%。对于所有非常早期接受治疗的婴儿，在生命的第一年可能不需要常规预防卡氏肺孢子虫肺炎。
临床试验注册
NCT02140255。
相似文献
1
Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life.
Clin Infect Dis. 2023 Feb 8;76(3):e744-e747. doi: 10.1093/cid/ciac695.
2
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
N Engl J Med. 2001 Jan 18;344(3):159-67. doi: 10.1056/NEJM200101183440301.
3
Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Expert Rev Anti Infect Ther. 2017 Sep;15(9):873-892. doi: 10.1080/14787210.2017.1364991. Epub 2017 Aug 21.
4
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
N Engl J Med. 2001 Jan 18;344(3):168-74. doi: 10.1056/NEJM200101183440302.
5
Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia.
J Microbiol Immunol Infect. 2017 Aug;50(4):547-548. doi: 10.1016/j.jmii.2016.03.008. Epub 2016 Mar 28.
6
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
PLoS One. 2011;6(12):e28570. doi: 10.1371/journal.pone.0028570. Epub 2011 Dec 16.
7
No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
J Int AIDS Soc. 2021 Jun;24(6):e25726. doi: 10.1002/jia2.25726.
8
Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
J Int AIDS Soc. 2012 Jan 26;15(1):1. doi: 10.1186/1758-2652-15-1.
9
Pneumocystis pneumonia in a person with a low CD4 count after stopping antiretroviral therapy.
AIDS Read. 2007 Dec;17(12):583-6, 593.
10
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
N Engl J Med. 1999 Apr 29;340(17):1301-6. doi: 10.1056/NEJM199904293401701.
引用本文的文献
1
Impact of Delayed Early Antiretroviral Therapy Initiation on Treatment Outcomes in Infant Macaques Exposed to SHIVAD8.
Viruses. 2025 Jun 14;17(6):849. doi: 10.3390/v17060849.
2
Intact HIV DNA decays in children with and without complete viral load suppression.
PLoS Pathog. 2025 Apr 4;21(4):e1013003. doi: 10.1371/journal.ppat.1013003. eCollection 2025 Apr.
3
High mortality following early initiation of antiretroviral therapy in infants living with HIV from three African countries.
EClinicalMedicine. 2024 May 23;73:102648. doi: 10.1016/j.eclinm.2024.102648. eCollection 2024 Jul.
4
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.
Lancet HIV. 2024 Jan;11(1):e20-e30. doi: 10.1016/S2352-3018(23)00236-9. Epub 2023 Dec 4.
5
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
J Acquir Immune Defic Syndr. 2023 Apr 15;92(5):393-398. doi: 10.1097/QAI.0000000000003147.
本文引用的文献
1
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
Lancet HIV. 2021 Mar;8(3):e149-e157. doi: 10.1016/S2352-3018(20)30274-5. Epub 2020 Nov 23.
2
Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency.
J Pediatric Infect Dis Soc. 2019 Nov 6;8(5):450-460. doi: 10.1093/jpids/piy087.
3
Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.
4
Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
Pediatrics. 2007 Jul;120(1):100-9. doi: 10.1542/peds.2006-2052.
5
Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
JAMA. 2006 Jul 19;296(3):292-300. doi: 10.1001/jama.296.3.292.
6
Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents.
Lancet. 2003 Dec 20;362(9401):2045-51. doi: 10.1016/s0140-6736(03)15098-2.
7
Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children.
Pediatr Infect Dis J. 2003 Jan;22(1):62-9. doi: 10.1097/00006454-200301000-00016.
8
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Lancet. 2000 Apr 15;355(9212):1331-2. doi: 10.1016/s0140-6736(00)02117-6.
9
Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
N Engl J Med. 1995 Mar 23;332(12):786-90. doi: 10.1056/NEJM199503233321206.
10
1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
MMWR Recomm Rep. 1995 Apr 28;44(RR-4):1-11.
Zotero 插件